Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Clinical Trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002982

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Drug: cytarabine
Drug: asparaginase
Drug: daunorubicin hydrochloride
Drug: methotrexate
Drug: therapeutic hydrocortisone
Drug: thioguanine

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-27

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 254

Registration Number: NCT00003593

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States

and more 233 locations

Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-12

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 392

Registration Number: NCT00002700

Locations: 🇸🇰
Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium

and more 41 locations

Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

Phase 3

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Promyelocytic Leukemia (M3)
Childhood Acute Promyelocytic Leukemia (M3)
Untreated Adult Acute Myeloid Leukemia
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions: Drug: tretinoin
Drug: daunorubicin hydrochloride
Drug: cytarabine
Drug: arsenic trioxide
Drug: mercaptopurine
Drug: methotrexate

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 420

Registration Number: NCT00003934

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Adult Acute Eosinophilic Leukemia
Adult Acute Erythroid Leukemia (M6)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Basophilic Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)

Interventions: Drug: cytarabine
Biological: aldesleukin
Other: clinical observation
Drug: daunorubicin hydrochloride
Biological: filgrastim
Drug: etoposide
Other: pharmacological study
Drug: valspodar
Drug: busulfan
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation